Humacyte (HUMA) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Product innovation and platform overview

• Introduced a first-in-class acellular tissue engineered vessel (ATEV) for cardiovascular repair, capable of being stored for up to 18 months and used without immunosuppression.

• Nearly 600 patients have been treated across multiple indications, with strong validation from partnerships with Fresenius Medical Care and the U.S. Department of Defense.

• The platform enables production of vessels of various sizes and shapes, supporting a pipeline for heart bypass and Type 1 diabetes applications.

• Engineered vessels repopulate with patient cells post-implantation, becoming living tissue and reducing infection risk.

Clinical development and regulatory progress

• Commercial-scale manufacturing has been operational since 2021, with a cell bank supporting decades of production.

• Lead indication targets traumatic injury repair, with pivotal trials supported by the Department of Defense and completed Phase III and II trials in dialysis access and peripheral artery disease.

• Humanitarian use in Ukraine demonstrated 94% patency and 100% limb salvage in war-injured patients.

• Combined civilian and wartime data showed 91.5% patency, <1% infection, and 4.5% amputation rates, outperforming synthetic grafts.

• BLA accepted by FDA in February; approval decision expected in coming weeks or months.

Market opportunity and commercialization plans

• Phase III trial in hemodialysis access met co-primary endpoints, showing significant improvement over standard fistulas.

• Subgroup analyses, especially for women and obese patients, are promising and will be shared soon.

• Commercial launch is ready upon approval, with manufacturing capacity for 8,000 vessels and modular expansion to 40,000.

• Partnership with Fresenius Medical Care expected to drive adoption in the U.S. and internationally.

• Initial sales force will be small due to the focused trauma market; manufacturing is highly automated and scalable.